SEARCH

SEARCH BY CITATION

References

  • 1
    Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297310.
  • 2
    Hertz MI, Aurora P, Benden C, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: Introduction to the 2011 annual reports. J Heart Lung Transplant 2011; 30: 10711077.
  • 3
    Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 13911316.
  • 4
    Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 2009; 28: 888893.
  • 5
    Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175: 507513.
  • 6
    Knoop C, Estenne M. Chronic allograft dysfunction. Clin Chest Med 2011; 32: 311326.
  • 7
    Palmer SM, Flake GP, Kelly FL, et al. Severe airway epithelial injury, aberrant repair and bronchiolitis obliterans develops after diacetyl instillation in rats. PLoS One 2011; 6: e17644.
  • 8
    Weigt SS, Wallace WD, Derhovanessian A, Saggar R, Lynch JP, Belperio JA. Chronic allograft rejection: Epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 2010; 31: 189207.
  • 9
    de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167: 490511.
  • 10
    Lee JC, Christie JD, Keshavjee S. Primary graft dysfunction: Definition, risk factors, short- and long-term outcomes. Semin Respir Crit Care Med 2010; 31: 161171.
  • 11
    Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect 2004 ; 6: 12191225.
  • 12
    Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 10101015.
  • 13
    Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010; 917108.
  • 14
    Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173: 10081015.
  • 15
    Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63: 10831089.
  • 16
    Buckley ST, Medina C, Kasper M, Ehrhardt C. Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011; 300: L548L559.
  • 17
    Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 12321241.
  • 18
    Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15(1 Pt 1): 115.
  • 19
    Eberlein M, Permutt S, Brown RH, et al. Supranormal expiratory airflow after bilateral lung transplantation is associated with improved survival. Am J Respir Crit Care Med 2011; 183: 7987.
  • 20
    Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51: 524532.
  • 21
    Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923936.
  • 22
    He M, Kubo H, Ishizawa K, et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1427L1436.
  • 23
    Englert JM, Hanford LE, Kaminski N, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008; 172: 583591.
  • 24
    Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M. The receptor for advanced glycation end products and its ligands: A new inflammatory pathway in lung disease? Mod Pathol 2006; 19: 14371445.
  • 25
    Queisser MA, Kouri FM, Konigshoff M, et al. Loss of RAGE in pulmonary fibrosis: Molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008; 39: 337345.
  • 26
    Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7: R817R824.
  • 27
    Pelaez A, Force SD, Gal AA, et al. Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation. Am J Transplant 2010; 10: 900907.
  • 28
    Parker MD, Chambers PA, Lodge JP, Pratt JR. Ischemia-reperfusion injury and its influence on the epigenetic modification of the donor kidney genome. Transplantation 2008; 86: 18181823.
  • 29
    Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 16411650.
  • 30
    Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735742.